-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
Empowering specialist capacity building
In June 2019, in order to accelerate the realization of the goals and tasks of Healthy China proposed in the "Healthy China 2030" Planning Outline, the State Council issued the "Opinions of the State Council on Implementing the Healthy China Action"
Mao Qun'an, deputy director of the Office of the Promotion Committee of the Healthy China Action Promotion Committee and director of the Department of Planning, Development and Informatization of the National Health and Health Commission, said that the Healthy China Action put forward the requirements of paying attention to the whole population and the whole life cycle of medical care and health services.
In terms of standardized diagnosis and treatment of tumors, the development of medical resources and the level of diagnosis and treatment in China is uneven, and there are differences in the level of standardized diagnosis and treatment in different regions, which is an urgent topic to be solved
Improve the scientific management of breast cancer
According to the latest global cancer burden data released by the World Health Organization's International Agency for Research on Cancer in 2020, the number of new cases of breast cancer in Chinese women in 2020 will reach 420,000, and there will be 120,000 deaths
The relevant person in charge of the Health News said that in various cancer types, whether it is molecular diagnosis, staging, and grading of cancer, or the application of targeted therapy, immunotherapy, endocrine therapy and other methods, experts in the field of breast cancer are often at the forefront
The launch of the "Promotion Project for Scientific Management of Breast Cancer" will promote the implementation of standardized diagnosis and treatment of breast cancer in local primary hospitals, further improve the level of standardized diagnosis and treatment of breast cancer, and bring survival benefits to more breast cancer patients
There are several important dimensions of scientific management: first, strengthen the capacity building and standardized management of relevant departments to make it compatible with the oncology diagnosis and treatment work carried out to ensure the quality of diagnosis and treatment; second, strictly implement relevant diagnosis and treatment norms and clinical paths, According to the basic situation of the patient, rationally select the treatment method and carry out standardized diagnosis and treatment; third, actively organize relevant disciplines to conduct consultations, case discussions or joint rounds, and formulate scientific and appropriate diagnosis and treatment plans; fourth, strengthen rehabilitation hospitals, nursing care The construction of hospitals and hospice care institutions should promote the establishment of long-term counterpart cooperation relationships with higher-level hospitals, and gradually build a whole-process management model for tumors
Supplementing Weaknesses with "Two Comprehensive" Health Management
The project was led by Professor Xu Binghe, academician of the Chinese Academy of Engineering, and Professor Wu Jiong, chairman of the Breast Cancer Professional Committee of the China Anti-Cancer Association, and formed an expert committee composed of 45 experts
As a malignant tumor with the highest cure rate and longest survival time in China, the diagnosis and treatment of breast cancer has entered the era of chronic disease management
With the continuous development of diagnosis and treatment technology and the clinical application of innovative drugs, the diagnosis and treatment of breast cancer has made great progress, but there is still a lot of room for improvement
Neoadjuvant therapy has outstanding clinical advantages, but in China, the development rate in 2017 was only 17%, which was significantly lower than the 40-80% in European and American countries
Standardize diagnosis and treatment to promote sustainable development
The "Breast Cancer Scientific Management Promotion Project" is planned to cover 297 hospitals in 30 provinces (autonomous regions and municipalities) in one year
Bian Xin, President of Roche Pharmaceuticals China, said: "The construction of a healthy China is the responsibility of the whole society.
As a leader in the medical and health industry and a leader in personalized medicine, Roche has been actively working with the government, medical institutions, associations and other social parties to explore The innovative cooperation model helps Chinese breast cancer patients obtain the most suitable treatment at the most suitable time through accurate typing and diagnosis.
In the
future, we will continue to actively fulfill our corporate social responsibility and help the goal of Healthy China 2030 to be realized as soon as possible
.
"
